| International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma SV Rajkumar, MA Dimopoulos, A Palumbo, J Blade, G Merlini, MV Mateos, ... The lancet oncology 15 (12), e538-e548, 2014 | 4949 | 2014 |
| International uniform response criteria for multiple myeloma BGM Durie, JL Harousseau, JS Miguel, J Blade, B Barlogie, K Anderson, ... Leukemia 20 (9), 1467-1473, 2006 | 3439 | 2006 |
| Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group International Myeloma Working Group British journal of haematology 121 (5), 749-757, 2003 | 2610 | 2003 |
| International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma S Kumar, B Paiva, KC Anderson, B Durie, O Landgren, P Moreau, ... The lancet oncology 17 (8), e328-e346, 2016 | 2467 | 2016 |
| Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma JF San Miguel, R Schlag, NK Khuageva, MA Dimopoulos, O Shpilberg, ... New England Journal of Medicine 359 (9), 906-917, 2008 | 2453 | 2008 |
| Revised international staging system for multiple myeloma: a report from International Myeloma Working Group A Palumbo, H Avet-Loiseau, S Oliva, HM Lokhorst, H Goldschmidt, ... Journal of clinical oncology 33 (26), 2863, 2015 | 2143 | 2015 |
| Hematological findings and complications of COVID‐19 E Terpos, I Ntanasis‐Stathopoulos, I Elalamy, E Kastritis, TN Sergentanis, ... American journal of hematology 95 (7), 834-847, 2020 | 2116 | 2020 |
| Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma M Dimopoulos, A Spencer, M Attal, HM Prince, JL Harousseau, ... New England Journal of Medicine 357 (21), 2123-2132, 2007 | 1817 | 2007 |
| Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors A Bamias, E Kastritis, C Bamia, LA Moulopoulos, I Melakopoulos, ... J Clin Oncol 23 (34), 8580-7, 2005 | 1602 | 2005 |
| Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma AK Stewart, SV Rajkumar, MA Dimopoulos, T Masszi, I Špička, A Oriol, ... New England Journal of Medicine 372 (2), 142-152, 2015 | 1580 | 2015 |
| Daratumumab, lenalidomide, and dexamethasone for multiple myeloma MA Dimopoulos, A Oriol, H Nahi, J San-Miguel, NJ Bahlis, SZ Usmani, ... New England Journal of Medicine 375 (14), 1319-1331, 2016 | 1575 | 2016 |
| Elotuzumab therapy for relapsed or refractory multiple myeloma S Lonial, M Dimopoulos, A Palumbo, D White, S Grosicki, I Spicka, ... New England Journal of Medicine 373 (7), 621-631, 2015 | 1500 | 2015 |
| Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma JR Berenson, A Lichtenstein, L Porter, MA Dimopoulos, R Bordoni, ... New England Journal of Medicine 334 (8), 488-493, 1996 | 1353 | 1996 |
| Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1 SV Rajkumar, JL Harousseau, B Durie, KC Anderson, M Dimopoulos, ... Blood, The Journal of the American Society of Hematology 117 (18), 4691-4695, 2011 | 1123 | 2011 |
| Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia RG Owen, SP Treon, A Al-Katib, R Fonseca, PR Greipp, ML McMaster, ... Seminars in oncology 30 (2), 110-115, 2003 | 1103 | 2003 |
| International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders A Dispenzieri, R Kyle, G Merlini, JS Miguel, H Ludwig, R Hájek, ... Leukemia 23 (2), 215-224, 2009 | 1035 | 2009 |
| Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma A Palumbo, SV Rajkumar, MA Dimopoulos, PG Richardson, J San Miguel, ... Leukemia 22 (2), 414-423, 2008 | 1019 | 2008 |
| Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and … RA Kyle, BGM Durie, SV Rajkumar, O Landgren, J Bladé, G Merlini, ... Leukemia 24 (6), 1121-1127, 2010 | 1013 | 2010 |
| Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label … J San Miguel, K Weisel, P Moreau, M Lacy, K Song, M Delforge, L Karlin, ... The lancet oncology 14 (11), 1055-1066, 2013 | 1011 | 2013 |
| Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ... Leukemia 26 (1), 149-157, 2012 | 1007 | 2012 |
Antonio PalumboUniversità di Torino; Torino ItalyVerified email at unito.it
